Aptar Digital Health has collaborated with SHL Medical to enhance patient experience in injectable therapies by integrating digital health solutions with advanced drug delivery systems.
This collaboration aims to extend SHL Medical’s connected device technologies through the integration of Aptar Digital Health’s software as a medical device (SaMD) platform.
Go deeper with GlobalData
The partnership will see SHL Medical’s devices, including the Molly Connected Cap, a smart add-on for the Molly autoinjector, benefit from Aptar Digital Health’s SaMD platform.
Aptar Digital Health said the integration is designed to improve the patient experience by offering digital support during self-administration of injectable therapies.
The SaMD platform is designed to provide digital health solutions tailored to the patient’s profile, disease state, and treatment plan.
SHL Medical plans to recommend Aptar Digital Health as a trusted digital partner.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAptar Digital Health president Sai Shankar said: “Embarking on a self-injection therapy and adhering to a consistent injection schedule can pose a challenge to patients in being actively involved in their treatment journey.
“By joining forces with SHL Medical, a world-class leader in innovative drug delivery systems, we aim to positively and durably change the experience of patients who must self-inject regularly.”
The collaboration between Aptar Digital Health and SHL Medical aims to develop comprehensive end-to-end solutions for the pharmaceutical industry.
These solutions focus on enhancing the patient experience during self-injection of innovative drugs such as GLP-1.
SHL Medical chief technical officer Ralph Howald said: “With our combined expertise, the partnership with Aptar Digital Health will serve as the first step in realising a thoroughly-needed digital ecosystem for injectable drugs, starting with a digital transformation that will impact the end-to-end value chain in the future.”
Earlier this year, Aptar signed an enterprise agreement with Biogen to develop digital health solutions aimed at enhancing care for patients with neurological and rare diseases.
